{"id":"W1996349490","doi":"10.1002/hep.26274","title":"Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients","year":2013,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Ribavirin; Medicine; Genotype; Randomized controlled trial; Internal medicine; Alpha (finance); Gastroenterology; Virology; Hepatitis C virus; Surgery; Biology; Virus; Gene; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003768998,0.0002863919,0.001708117,0.000389981,0.00003102801,0.00001172298,0.0001672088,0.000216325,0.00135085],"category_scores_gemma":[0.0005782383,0.0001976814,0.0002377006,0.0002993973,0.0003371841,0.0001004581,0.00006328889,0.0002353491,0.0003859139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003468143,"about_ca_system_score_gemma":0.0003814986,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009132766,"about_ca_topic_score_gemma":0.0004909445,"domain_scores_codex":[0.9969839,0.00080993,0.0008517764,0.0004266835,0.0003553781,0.0005722974],"domain_scores_gemma":[0.9984786,0.0003686748,0.0002016337,0.0004861549,0.000293773,0.0001711805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7630224,0.001852216,0.1291389,0.0000494538,0.0003234476,0.00007150113,0.0009713911,0.000001022316,0.001397047,0.0001029113,0.0006637436,0.1024059],"study_design_scores_gemma":[0.9770011,0.009149282,0.004370051,0.00004083263,0.00005515149,0.000007278267,0.00002649863,0.002740881,0.002111335,0.0001092967,0.004205199,0.0001831255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869223,0.0003576908,0.00003666984,0.0009789187,0.0002698137,0.006712877,0.00001107729,0.0000441638,0.004666451],"genre_scores_gemma":[0.9958389,0.001360186,0.0002537059,0.0002104577,0.00007985395,0.001316702,0.00007293167,0.00005082853,0.0008163803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2139787,"threshold_uncertainty_score":0.999562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03851315673015657,"score_gpt":0.3267807605196495,"score_spread":0.2882676037894929,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}